What you should know:
1. RedHill and Salix entered into a licensing agreement in 2014 for the therapy, which is now in development.
2. The pill is a flavorless, solid oral preparation that eases patient burden and improves the likelihood of a successful outcome.
3. Researchers recently completed a phase 2A study of a past version of the pill, which concluded with 62 patients demonstrating comparable bowel preparation to traditional preparation solutions.
4. RedHill CEO Dror Ben-Asher said the reacquisition of RHB-106 aligned with the company’s commercial activities in the U.S.
More articles on surgery centers:
Supply chain tip of the week: Grow your ASC sustainably
How ASCs purchase devices, equipment: 3 insights
Supply chain tip of the week: Streamline supply consumption
